Navigation Links
US Oncology Research Investigators Participated in Studies That Will be Presented at the 2010 American Society of Hematology Annual Meeting and Exposition
Date:12/3/2010

THE WOODLANDS, Texas, Dec. 3, 2010 /PRNewswire/ -- US Oncology, Inc., the nation's leading integrated oncology company, announced today that three investigators affiliated with US Oncology Research participated in studies that will be presented orally at the 52nd American Society of Hematology (ASH) Annual Meeting and Exposition at the Orange County Convention Center in Orlando, Fla. Dec. 4-7. Five other investigators in the US Oncology Research Network participated in a study that will be displayed as a poster during the conference.

(Logo: http://photos.prnewswire.com/prnh/20100517/DA06089LOGO)

Jeff Sharman, M.D., medical oncologist with Willamette Valley Cancer Institute and Research Center – Riverbend, participated in a study that will be presented in an oral presentation regarding the safety of the drug, PCI-32765, used by patients with recurrent B-cell lymphoma. The study, titled "Phase I Dose-escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma (PCYC-04753)," identified a range of biologically meaningful doses for subsequent Phase II testing.

"It is exciting to work with this new class of drugs," said Dr. Sharman. "I believe targeted inhibitors of b-cell receptor signaling will soon be an effective, well-tolerated treatment option available for our patients with CLL and NHL."

Dr. Sharman participated in another study regarding the same drug titled "APCYC-1102-CA: Phase 1b Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leuk
'/>"/>

SOURCE US Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Presentation of PROVENGE Data at the American Society of Hematology and the Society of Urologic Oncology Annual Meetings
2. Sagent Pharmaceuticals Adds to Its Oncology Portfolio With Launch of Topotecan Hydrochloride for Injection
3. Access Pharmaceuticals ProLindac™ and CobaCyte™ Oncology Research Displayed at the Innovations in Cancer Prevention and Research Conference, November 17-19, 2010
4. Generex Oncology Awarded Two IRS Therapeutic Discovery Project Grants
5. D3 Radiation Oncology Solutions has Completed Collaborative Commissioning of Two Varian TrueBeam Medical Linear Accelerators at the John Theurer Cancer Center, Hackensack University Medical Center
6. Elekta Introduces MOSAIQ Data Director, Image and Data Hub for Oncology
7. Philips Showcases Integrated Radiation Oncology Suite to Simplify Treatment Planning
8. Philips Introduces High Field Open MRI for Radiation Oncology
9. Accurays CyberKnife VSI System Featured at 2010 American Society for Radiation Oncology (ASTRO) Annual Meeting
10. D3 Launches New Suite of Solutions, including the First Radiation Oncology Clinical Pathways Program, at the ASTRO Annual Meeting, October 31 - November 3, 2010 in San Diego
11. Prostate Oncology Specialists Among First in the Nation to Treat Advanced Prostate Cancer Patients With PROVENGE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015  Delays in ... projects can slow down the decision-making process, resulting ... therefore, absolutely critical for biopharmaceutical companies to develop ... approval process for quicker and more meaningful insights. ... Best Practices, LLC, nearly three-quarters of benchmarked study ...
(Date:8/28/2015)... August 28, 2015 According to ... Tumor (Breast, Lung, Prostate) Type (Protein & Genetic Biomarkers) ... Discovery, Prognostic) & Geography - Global Forecast to 2020", ... to reach around 17,689.0 Million USD by 2020 at ... 2015 to 2020. Browse 191 Tables ...
(Date:8/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/686gwf/investigation ) ... on China,s Bevacizumab Market ,2010-2019" report to their ... name of Avastin, bevacizumab injection is the first angiogenesis ... approved by CFDA to treat metastatic colorectal cancer. Currently, ... all come from Roche and its subsidiary Genectech. In ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 5Investigation Report on China's Bevacizumab Market 2015-2019 2
... July 12 Ferring Pharmaceuticals Inc., the makers of ... Bat for the Cure charity, in an effort to "strike-out ... the organization,s Minor League Baseball initiative across the country. FIRMAGON® is ... , , ...
... (B. Braun) announced today the availability of large volume heparin infusion solutions. , ... (Logo:   http://photos.prnewswire.com/prnh/20081022/NYW008LOGO ) , ...   http://www.newscom.com/cgi-bin/prnh/20081022/NYW008LOGO ) , , , ... States Pharmacopeia (USP) standards for heparin products released by the U.S. Food and Drug Administration ...
Cached Medicine Technology:Ferring Pharmaceuticals' FIRMAGON® Named Official Sponsor of Ed Randall's Bat for the Cure 2Ferring Pharmaceuticals' FIRMAGON® Named Official Sponsor of Ed Randall's Bat for the Cure 3Ferring Pharmaceuticals' FIRMAGON® Named Official Sponsor of Ed Randall's Bat for the Cure 4B. Braun Large Volume Heparin Infusion Solutions Now Available 2B. Braun Large Volume Heparin Infusion Solutions Now Available 3
(Date:8/31/2015)... , ... August 31, 2015 , ... ... Month 2015 in September by sharing the facts about the role of heredity ... and BRCA2 genetic mutations because of Angelina Jolie Pitt’s decisions to have both ...
(Date:8/31/2015)... ... August 31, 2015 , ... In preparation for this November’s National Family Caregivers ... personal sound amplifier, is offering caregivers “7 Reasons to Care about Hearing Health.” The ... with a variety of home healthcare challenges, specifically as they relate to caring for ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... airway management device that could effectively deliver oxygen with a lower risk of ... a better way, I invented the Adam Device." , The Adam Device offers ...
(Date:8/31/2015)... ... ... For 12 years, since 2004, the Mesothelioma Applied Research Foundation ... . On this day, and in the weeks leading up to it, the Meso ... cause. , “One of the ways a person can be involved is by wearing ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... A year ... the team is preparing to release a new issue commemorating the successful first year. ... information they need for a potentially difficult time in their lives,” says Melissa Wolfert, ...
Breaking Medicine News(10 mins):Health News:Foundation for Women’s Cancer Alerts Women to the Facts About the Role of Heredity in Gynecologic Cancers 2Health News:Foundation for Women’s Cancer Alerts Women to the Facts About the Role of Heredity in Gynecologic Cancers 3Health News:Foundation for Women’s Cancer Alerts Women to the Facts About the Role of Heredity in Gynecologic Cancers 4Health News:Etymotic Offers Caregivers “7 Reasons to Care about Hearing Health” 2Health News:Etymotic Offers Caregivers “7 Reasons to Care about Hearing Health” 3Health News:InventHelp® Client's Invents Medical Device to Restore Respiratory Function (BGF-905) 2Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 2Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 3Health News:Seniors Guide Magazine Celebrates Its First Year in Columbus With A Special Anniversary Issue 2Health News:Seniors Guide Magazine Celebrates Its First Year in Columbus With A Special Anniversary Issue 3
... reduce infant mortality in the U.S., according to a study ... A 10 percent increase in hospital use of basic ... births, the study found. A complete national transition to electronic ... the U.S. Many health professionals have advocated electronic records ...
... May 18, 2011 The American Society for Gastrointestinal ... of its program specifically dedicated to promoting quality in ... the United States. The ASGE Endoscopy Unit Recognition Program ... privileging, quality assurance, endoscopy reprocessing and CDC infection control ...
... 18 (HealthDay News) -- A flame retardant banned years ago in ... is among a number of potentially toxic flame retardants found in ... chairs, a new study reports. Flame retardants are used to ... number of products -- catching fire, and to slow the rate ...
... , WEDNESDAY, May 18 (HealthDay News) -- Deprivation and ... new study suggests. Researchers examined DNA samples collected ... Romania taking part in a long-term study. Some of ... transferred to high-quality foster care at different ages. ...
... you run a mile? If you,re middle-aged, the answer could ... stroke over the next decade or more. In two separate ... a middle-age person can run a mile can help predict the ... men and could be an early indicator of cardiovascular disease for ...
... care in the United States says that the rapidly growing ... ill patients raises serious concerns about whose interests are being ... those of dying patients and their loved ones. "Under ... of interest between a company,s drive to maximize profits and ...
Cached Medicine News:Health News:Electronic medical records lower infant mortality, study finds 2Health News:ASGE recognizes 30 endoscopy units for quality and safety 2Health News:ASGE recognizes 30 endoscopy units for quality and safety 3Health News:Potentially Toxic Flame Retardants Found in Baby Products 2Health News:Early Adversity May Shorten Child's Life 2Health News:Simple fitness test could predict long-term risk for heart attack, stroke in middle-aged people 2Health News:Simple fitness test could predict long-term risk for heart attack, stroke in middle-aged people 3Health News:Rise of for-profit hospice industry raises troubling questions, new study says 2